Identification of targetable FGFR gene fusions in diverse cancers.

  title={Identification of targetable FGFR gene fusions in diverse cancers.},
  author={Yi-Mi Wu and Fengyun Su and Shanker Kalyana-Sundaram and Nickolay A. Khazanov and Bushra Ateeq and Xuhong Cao and Robert J. Lonigro and Pankaj Vats and Rui Wang and Su-Fang Lin and Ann-Joy Cheng and Lakshmi Priya Kunju and Javed Siddiqui and Scott A. Tomlins and Peter Wyngaard and Seth Sadis and Sameek Roychowdhury and Maha H.A. Hussain and Felix Y. Feng and Mark M. Zalupski and Moshe Talpaz and Kenneth J. Pienta and Daniel R. Rhodes and Dan R. Robinson and Arul M. Chinnaiyan},
  journal={Cancer discovery},
  volume={3 6},
Through a prospective clinical sequencing program for advanced cancers, four index cases were identified which harbor gene rearrangements of FGFR2, including patients with cholangiocarcinoma, breast cancer, and prostate cancer. After extending our assessment of FGFR rearrangements across multiple tumor cohorts, we identified additional FGFR fusions with intact kinase domains in lung squamous cell cancer, bladder cancer, thyroid cancer, oral cancer, glioblastoma, and head and neck squamous cell… 

Figures from this paper

Identification of recurrent FGFR3 fusion genes in lung cancer through kinome‐centred RNA sequencing
This approach provides a global overview of kinase fusion events, irrespective of the identity of the fusion partner, and identifies numerous genetic alterations impacting fibroblast growth factor receptor 3 in lung squamous cell carcinoma and a novel ALK fusion partner in lung adenocarcinoma.
Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours
The ability to exploit the unique targetability of FGFR fusions proves that FGFR‐derived therapies could have a promising future in cancer therapeutics, and understanding the diverse mechanisms ofFGFR fusion formation and their oncogenic potential will shed light on the impact of FG FR‐derived therapy in the future.
FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention
The most frequent FGFR aberrations in human cancer are described and the different approaches employed for the detection of FGFR fusions are discussed and the potential role of these genomic alterations as prognostic/predictive biomarkers are discussed.
FGFR3–TACC3: A novel gene fusion in cervical cancer
Gene Fusions in Prostate Cancer
As the most specific known biomarker in prostate cancer, ETS gene fusions may have utility in tissue based diagnosis, risk stratification of precursor lesions, early detection, and distinguishing between clinically aggressive and indolent cases of prostate cancer.
Incidence of FGFR2 Amplification and FGFR2 Fusion in Patients with Metastatic Cancer Using Clinical Sequencing
The clinicopathological features of FGFR2 amplification and fusion in gastrointestinal tract/genitourinary tract cancers and their effects on overall survival and progression-free survival are examined to screen solid cancer patients forFGFR2 aberrations in oncology clinic.
Landscape of gene fusions in epithelial cancers: seq and ye shall find
Prioritization of potential oncogenic “drivers” from “passenger” fusions, and functional characterization of potentially actionable gene fusions across diverse tissue types, will help translate findings into clinical applications.
FGFR2-TSC22D1, a novel FGFR2 fusion gene identified in a patient with colorectal cancer: A case report
This report reports the first case of CRC harboring FGFR2-TSC22D1, which enriches theFGFR2 fusion spectrum and might be effective in the later treatment for this patient.
Transcriptome Meta-Analysis of Lung Cancer Reveals Recurrent Aberrations in NRG1 and Hippo Pathway Genes
It is shown that higher numbers of gene fusions is an independent prognostic factor for poor survival in lung cancer and suggests that NRG1, NF1 and Hippo pathway fusions may play important roles in tumors without known driver mutations.
Detection of Known and Novel FGFR Fusions in Non–Small Cell Lung Cancer by Comprehensive Genomic Profiling
  • A. QinAdrienne Johnson S. Gadgeel
  • Medicine, Biology
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2019


Functionally Recurrent Rearrangements of the MAST Kinase and Notch Gene Families in Breast Cancer
It is shown that recurrent gene rearrangements have key roles in subsets of carcinomas and suggest that transcriptome sequencing could identify individuals with rare, targetable gene fusions.
The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma.
It is demonstrated that the FGFR3-TACC3 gene fusion is expressed in human cancer and generates an oncogenic protein that promotes tumorigenesis in glioblastoma.
Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma
In mice, FGFR inhibitors slowed the growth of tumors driven by the TACC-FGFR gene, suggesting that a subset of glioblastoma patients may benefit from these types of drugs, and a fusion gene detected in a small subset of human brain tumors encodes a potentially druggable target.
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer.
Oncogenic FGFR3 gene fusions in bladder cancer
As urothelial cell lines with FGFR3 fusions are extremely sensitive to FGFR-selective agents, the presence of a fusion gene may aid in selection of patients forFGFR-targeted therapy.
The transcriptional landscape and mutational profile of lung adenocarcinoma.
The first large scale RNA sequencing study of lung adenocarcinoma is presented, demonstrating its power to identify somatic point mutations as well as transcriptional variants such as gene fusions, alternative splicing events, and expression outliers.
Targeting mutant fibroblast growth factor receptors in cancer.
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
It is shown that a small inversion within chromosome 2p results in the formation of a fusion gene comprising portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene in non-small-cell lung cancer (NSCLC) cells.
Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
The mutations present in advanced cancers can be identified by integrative high-throughput sequencing to enable biomarker-driven clinical trials and, ultimately, treatment and the authors tested this approach by extensively characterizing cancers in several patients and then convening a Sequencing Tumor Board of experts to determine the appropriate treatment.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients, and the drug resulted in grade 1 or 2 gastrointestinal side effects.